<?xml version="1.0" encoding="UTF-8"?>
<paload id="" version="">
	<toplevel>
		<routedMedId>75268</routedMedId>
		<routedMedName>Velcade injection</routedMedName>
		<routedGenericName>bortezomib injection</routedGenericName>
		<etcIds>
			<etc_id>5729</etc_id>
		</etcIds>
		<medIds>
			<medId>449727</medId>
		</medIds>
	</toplevel>
	<diagnoses>
		<diagnosis>
			<?oxy_comment_start author="paulnguyen" timestamp="20150205T153315-0800" comment="C: This is a type of non-Hodgkin&apos;s lymphoma.  MCG has the &apos;non-Hodgkin&apos; as part of their indication where as FDB does not."?>
			<fqn><?oxy_comment_end?>Mantle Cell Lymphoma-relapsed or refractory</fqn>
			<age>
				<ageRangeType>ge</ageRangeType>
				<ageRangeMin>18</ageRangeMin>
				<ageRangeMax/>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.13699</icd9>
			<symbolic>Velcade-MCL</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name>relapse or refractory</name>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name>Hematology &amp; Oncology</name>
					<code>207RH0003X</code>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name>Pregnancy</name>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>exclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>nocode</typeName>
						<treatment>
							<treatmentLine>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<treatment>
							<dosing/>
							<rating>atherapy</rating>
							<treatmentLine>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</concurrenttherapy>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>nocode</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
			<concurrentTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</concurrentTherapyExclusion>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Velcade (bortezomib) for injection. Physician Prescribing Information [Internet] Millennium Pharmaceuticals, Inc. 2012 Oct Accessed at: http://www.velcade.com/. [created 2003; accessed 2013 Dec 2]</reference>
				<reference>Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Current Cancer Drug Targets 2011;11(3):239-53.</reference>
				<reference>Goy A, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Annals of Oncology 2009;20(3):520-5. DOI: 10.1093/annonc/mdn656.</reference>
				<reference>Non-Hodgkin's lymphomas. NCCN Clinical Practice Guidelines in Oncology [Internet] National Comprehensive Cancer Network (NCCN). v 2.2013; 2013 Sep Accessed at: www.nccn.org/professionals/physician_gls/f_guidelines.asp. [accessed 2013 Oct 9]</reference>
				<reference>Holkova B, Grant S. Proteasome inhibitors in mantle cell lymphoma. Best Practice and Research. Clinical Haematology 2012;25(2):133-41. DOI: 10.1016/j.beha.2012.04.007.</reference>
				<reference>Multiple myeloma. NCCN Clinical Practice Guidelines in Oncology [Internet] National Comprehensive Cancer Network (NCCN). v 1.2014; 2013 Sep Accessed at: www.nccn.org/professionals/physician_gls/f_guidelines.asp. [accessed 2013 Oct 9]</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Multiple Myeloma</fqn>
			<age>
				<ageRangeType>ge</ageRangeType>
				<ageRangeMin>18</ageRangeMin>
				<ageRangeMax/>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.480</icd9>
			<symbolic>Velcade-MM</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name>Hematology &amp; Oncology</name>
					<code>207RH0003X</code>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name>Pregnancy</name>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>exclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>nocode</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<treatment>
							<dosing/>
							<rating>rtherapy</rating>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</concurrenttherapy>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
			<concurrentTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</concurrentTherapyExclusion>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Velcade (bortezomib) for injection. Physician Prescribing Information [Internet] Millennium Pharmaceuticals, Inc. 2012 Oct Accessed at: http://www.velcade.com/. [created 2003; accessed 2013 Dec 2]</reference>
				<reference>Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Current Cancer Drug Targets 2011;11(3):239-53.</reference>
				<reference>Multiple myeloma. NCCN Clinical Practice Guidelines in Oncology [Internet] National Comprehensive Cancer Network (NCCN). v 1.2014; 2013 Sep Accessed at: www.nccn.org/professionals/physician_gls/f_guidelines.asp. [accessed 2013 Oct 9]</reference>
				<reference>Barosi G, et al. SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. Annals of Hematology 2012;91(6):875-88. DOI: 10.1007/s00277-012-1445-y.</reference>
				<reference>Mikhael JR, et al. Management of newly diagnosed symptomatic multiple nyeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clinic Proceedings 2013;88(4):360-76. DOI: 10.1016/j.mayocp.2013.01.019.</reference>
				<reference>Wang A, et al. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. Annals of Hematology 2012;91(11):1779-84. DOI: 10.1007/s00277-012-1520-4.</reference>
				<reference>Delforge M. Bortezomib for previously untreated multiple myeloma. Expert Opinion on Pharmacotherapy 2011;12(16):2553-64. DOI: 10.1517/14656566.2011.622266.</reference>
				<reference>San Miguel JF, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine 2008;359(9):906-17. DOI: 10.1056/NEJMoa0801479.</reference>
				<reference>Spicka I, Mateos MV, Redman K, Dimopoulos MA, Richardson PG. An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation. Immunotherapy 2011;3(9):1033-40. DOI: 10.2217/imt.11.104.</reference>
				<reference>Mateos MV, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. Journal of Clinical Oncology 2010;28(13):2259-66. DOI: 10.1200/JCO.2009.26.0638.</reference>
				<reference>Piro E, Molica S. A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence? Acta Haematologica 2011;126(3):163-8. DOI: 10.1159/000328417.</reference>
				<reference>Rosinol L, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 2012;120(8):1589-96. DOI: 10.1182/blood-2012-02-408922.</reference>
				<reference>Sonneveld P, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. Journal of Clinical Oncology 2012;30(24):2946-55. DOI: 10.1200/JCO.2011.39.6820.</reference>
				<reference>Ludwig H, et al. European perspective on multiple myeloma treatment strategies: update following recent congresses. Oncologist 2012;17(5):592-606. DOI: 10.1634/theoncologist.2011-0391.</reference>
				<reference>Wang L, Ran X, Wang B, Sheng Z, Liu L. Novel agents-based regimens as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. Hematological Oncology 2012;30(2):57-61. DOI: 10.1002/hon.1007.</reference>
				<reference>Garderet L, et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology 2012;30(20):2475-82. DOI: 10.1200/JCO.2011.37.4918.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Amyloidosis-inconclusive or non-supportive evidence</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.779</icd9>
			<symbolic/>
			<rating>recommendedDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>nocode</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<treatment>
							<dosing/>
							<rating>rtherapy</rating>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</concurrenttherapy>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
			<concurrentTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</concurrentTherapyExclusion>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Venner CP, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012;119(19):4387-90. DOI: 10.1182/blood-2011-10-388462.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Non-Hodgkin Follicular Lymphoma-inconclusive or non-supportive evidence</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9/>
			<symbolic/>
			<rating>recommendedDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>nocode</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<treatment>
							<dosing/>
							<rating>rtherapy</rating>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</concurrenttherapy>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
			<concurrentTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</concurrentTherapyExclusion>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Coiffier B, et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncology 2011;12(8):773-84. DOI: 10.1016/S1470-2045(11)70150-4.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Solid Organ Transplant-inconclusive or non-supportive evidence</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9/>
			<symbolic/>
			<rating>recommendedDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>nocode</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<treatment>
							<dosing/>
							<rating>rtherapy</rating>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</concurrenttherapy>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
			<concurrentTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</concurrentTherapyExclusion>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Sadaka B, Alloway RR, Woodle ES. Clinical and investigational use of proteasome inhibitors for transplant rejection. Expert Opinion on Investigational Drugs 2011;20(11):1535-42. DOI: 10.1517/13543784.2011.618494.</reference>
				<reference>Walsh RC, Alloway RR, Girnita AL, Woodle ES. Proteasome inhibitor-based therapy for antibody-mediated rejection. Kidney International 2012;81(11):1067-74. DOI: 10.1038/ki.2011.502.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Waldenstrom's Macroglobulinemia-inconclusive or non-supportive evidence</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.13434</icd9>
			<symbolic/>
			<rating>recommendedDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>nocode</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<treatment>
							<dosing/>
							<rating>rtherapy</rating>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</concurrenttherapy>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
			<concurrentTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</concurrentTherapyExclusion>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Treon SP, et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. Journal of Clinical Oncology 2009;27(23):3830-5. DOI: 10.1200/JCO.2008.20.4677.</reference>
				<reference>Ghobrial IM, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. Journal of Clinical Oncology 2010;28(8):1422-8. DOI: 10.1200/JCO.2009.25.3237.</reference>
				<reference>Agathocleous A, et al. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinaemia. British Journal of Haematology 2010;151(4):346-53. DOI: 10.1111/j.1365-2141.2010.08340.x.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
	</diagnoses>
	<precautions>
		<geriatric>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</geriatric>
		<pregnancy>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</pregnancy>
		<pediatric>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</pediatric>
		<lactation>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</lactation>
		<allergy>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</allergy>
		<sideEffect>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</sideEffect>
		<drugDisease>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</drugDisease>
	</precautions>
	<lists>
	</lists>
</paload>
